Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing

SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced positive preliminary, first-in-human results from the single-ascending-dose portion of its global Phase 1/1b trial of ZL-1503, an internally discovered, long-acting IL-13/IL-31 receptor alpha (Rα) bispecific antibody. Findings from the study will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scien

Please leave this field empty

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.

Please check your Inbox or Spam folder now to confirm your subscription.